[Ceftriaxone, a long-acting cephalosporin. Microbiological, kinetic and clinical study].
Ceftriaxone effectively inhibited 332 out of 452 (73.45%) bacterial strains in vitro tests. 291 out of 365 (79.69%) gram negative and 41 out of 87 (47.12%) gram positive strains were inhibited. The tests showed ceftriaxone to be more effective than cephalothin, cephotaxime, cephuroxime, cephamandol and cephoxitin. Kinetic tests showed that cephtriaxone has a plasmatic half life of 7.25 hrs. 24 hours after administration of a 1000 mg venous bolus the drug was still present in the blood. Urinary elimination over a 24 hr. period amounted to means 486.8 mg (48.68%). The drug has liquor transfer capacity. 37 of the 38 patients treated showed complete clinical or clinicobacteriological cure. Improvement was noted in the 38th.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D002443:Ceftriaxone; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D008581:Meningitis / Q000188:drug therapy; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy
D002443:Ceftriaxone; D002439:Cefotaxime
Ceftriaxone, cefalosporina "long acting". Ricerca microbiologica, cinetica e clinica.